ReviewMolecules (Basel, Switzerland)2025
The Role of Plectin Dysregulation in Cancer: Recent Advances.
Review in Molecules (Basel, Switzerland), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Role of Mechanotransduction in Cancer: A Complex Problem Involving Gene Mutations and Altered Levels of Connection Components.Biomolecules · 2026Review
- Epiplakin expression in non-melanoma skin cancer: associations with epithelial-mesenchymal transition markers and tumor invasion.Anais brasileiros de dermatologiaArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Plectin is a key cytolinker protein that functions as an integrator of the cytoskeletal networks by crosslinking intermediate filaments with actin filaments and microtubules. Mutations or function deficiencies of plectin lead to tissue disorders, particularly affecting the skin, muscle, and nervous tissues. Interestingly, plectin dysregulation in cancer, characterized by aberrant expression and mislocalization, has been increasingly observed, suggesting distinct roles in tumorigenesis and progression. Here, we focus on recent advances regarding the roles of plectin dysregulation in promoting cell proliferation, suppressing cell apoptosis, sustaining the stemness of cancer stem cells, and driving invasion and metastasis. We also discuss its bidirectional interplay with the tumor microenvironment, including modulating immune and inflammatory responses, promoting angiogenesis, sensing and transmitting mechanical cues from the extracellular matrix, and contributing to matrix remodeling. Finally, we highlight emerging therapeutic strategies that target plectin dysregulation with anticancer activity. By summarizing these advances, we aim to enhance the understanding of plectin dysregulation in cancer and illuminate its potential as a therapeutic target.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.